Publications by authors named "Helle Linnebjerg"

Claim this Profile
T
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations.
Jesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, Rongrong Rosa Jiang, Carol Kuo, Helle Linnebjerg

Nucleic Acids Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies.
Kausik K Ray, Helle Linnebjerg, Laura F Michael, Xi Shen, Xiaosu Ma

J Am Coll Cardiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lepodisiran for Elevated Lipoprotein(a)-Reply.
Steven E Nissen, Helle Linnebjerg, Stephen J Nicholls

JAMA· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.
Steven E Nissen, Helle Linnebjerg, Xi Shen, Kathy Wolski, Xiaosu Ma

JAMA· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
Stephen J Nicholls, Steven E Nissen, Cynthia Fleming, Shweta Urva, Jeffrey Suico, Helle Linnebjerg

JAMA· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
Ronnie Aronson, Torben Biester, Jennifer Leohr, Robyn Pollom, Helle Linnebjerg

Diabetes Obes Metab· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
Jennifer K Leohr, Mary Anne Dellva, Elizabeth LaBell, David E Coutant, Helle Linnebjerg

Clin Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
Xiaosu Ma, Charles T Benson, Randy Prescilla, Shuyu Zhang, Helle Linnebjerg

J Diabetes Sci Technol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects.
Hui Liu, Feng Wang, Yongjia Ji, Tianyang Ma, Hongying Li, Helle Linnebjerg

Clin Pharmacol Drug Dev· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data.
Jennifer Leohr, Mary Anne Dellva, Kallin Carter, Elizabeth LaBell, Helle Linnebjerg

Clin Pharmacokinet· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial.
Helle Linnebjerg, Qianyi Zhang, Elizabeth LaBell, Mary Anne Dellva, David E Coutant

Clin Pharmacokinet· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study.
Jennifer Leohr, Mary Anne Dellva, David E Coutant, Elizabeth LaBell, Tim Heise, Helle Linnebjerg

Clin Pharmacokinet· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
Tim Heise, Helle Linnebjerg, David Coutant, Elizabeth LaBell, Eric Zijlstra

Diabetes Obes Metab· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Jennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, David E Coutant, Oliver Klein, Helle Linnebjerg

Clin Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects.
Helle Linnebjerg, Elizabeth Smith LaBell, Mary Anne Dellva, David E Coutant, Jennifer Leohr

Diabetes Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
Niels K Porksen, Helle Linnebjerg, Eric Chen Quin Lam, Parag Garhyan, Alok Pachori

Diabetes Obes Metab· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Rakel F Johansen, Esben Søndergaard, Helle Linnebjerg, Parag Garhyan, Eric C Q Lam

Diabetes Obes Metab· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
Xin Zhang, Eric Chen Quin Lam, Mary E Seger, David Coutant, Laiyi Chua, Helle Linnebjerg

Clin Pharmacol Drug Dev· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Katrin Tiffner, Beate Boulgaropoulos, Christian Höfferer, Thomas Birngruber, Niels Porksen, Helle Linnebjerg

Diabetes Technol Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Niels Porksen, Helle Linnebjerg, Parag Garhyan, Eric C Q Lam, Mary P Knadler

Diabetes Obes Metab· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Helle Linnebjerg, Eric Chen Quin Lam, Xin Zhang, Mary E Seger, David Coutant

Diabetes Obes Metab· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
Helle Linnebjerg, Siak Leng Choi, Eric Chen Quin Lam, Kenneth F Mace, Teri S Hodgson

Clin Pharmacol Drug Dev· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL.
Amparo de la Peña, Mary Seger, Danny Soon, Adam J Scott, Shobha R Reddy, Helle Linnebjerg

Clin Pharmacol Drug Dev· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
Helle Linnebjerg, Eric Chen Quin Lam, Mary E Seger, David Coutant, Laiyi Chua

Diabetes Care· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium.
Simon Heller, Börje Darpö, Malcolm I Mitchell, Helle Linnebjerg, Derek J Leishman

Am Heart J· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis